Skip to main content

This job has expired

You will need to login before you can apply for a job.

Director, Screening and Genetic Perturbations

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
May 12, 2022

View more

Discipline
Science/R&D, Genetics
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Genetown, Best Places to Work

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

Intellia is looking for an experienced Director of Screening to lead a highly cross-functional team in advancing our research programs and platform improvements. In this essential role, you will lead a team of scientists focused on executing and developing methods for high throughput qualification of guide RNAs. Within this leadership role, you will generate data on gene editing systems to advance programs to the clinic as well as support the advancement of platform improvements and novel nucleases into therapeutic programs. This is a highly visible leadership position interacting across R&D integral to advancing therapeutic programs and advancing innovative platform solutions. In this role you will:

  • Mentor and manage a team of scientists focused on the development and implementation of screening methods across relevant primary cell types to support in vivo and cell therapy emerging pipelines

  • Collaborate across Platform Innovation and Delivery Innovation to advance novel nucleases as well as guide and message optimization and delivery approaches

  • Work closely with automation, computational biology, and software engineering to implement high throughput processes and data analysis

  • Act as functional representative on emerging program and platform teams developing strategy and aligning resources

  • Work closely with Alliance Management and Business Development to support partnership programs and new opportunities

  • Partner with research leads to assess screening and genetic perturbation needs across all functions including chemistry, gene editing, disease biology, and cell therapy

  • Prioritize requests and implement work plans to outline project expectations, assess resource needs, and ensure accountability both within the team and with stakeholders

About You:

The Director of Screening will have demonstrated leadership in high throughput screening and NGS methodologies, cell biology expertise, experience with gene editing approaches, and process optimization.

  • BS/MS/Ph.D. with at least 10 years directly relevant industry experience

  • Strong leadership and communication skills as well as a team-centric approach to management

  • Experience managing and mentoring scientists

  • Expertise in development, validation, optimization, scale-up of methods to automated platforms, and SOP implementation for high throughput screening applications

  • Manage workflow, organize, meet deadlines and work in a dynamic fast-paced environment

Meet your future team:

You will lead a critical core function of talented, innovative, passionate scientists partnering with genomics, computational biology, software engineering, and automation supporting and building screening processes and data to advance the pipeline and platform. We are accountable for enabling our programs in early research to reach development candidate nomination through regulatory filing and into clinical trials as well as support our internal platform optimization efforts in both the in vivo and cell therapy space.

In this key leadership role, you will report directly to the Senior Director, AEGIS (Automation, Engineering, Genomics, Informatics, and Screening), who instills a culture of teamwork, respect, inclusion, collaboration, and communication ensuring that each team member strives to reach their professional and personal potential.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert